患者を末期腎不全にしないための CKD診療のコツ

出版社: 文光堂
著者:
発行日: 2013-05-06
分野: 臨床医学:内科  >  腎臓
ISBN: 9784830681516
電子書籍版: 2013-05-06 (第1版第2刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

5,280 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,280 円(税込)

商品紹介

若手医師がCKD患者を受け持ったら,どのように管理してゆけばよいのか.日本のCKD診療の第一人者らによる,最新の診療エッセンスを解りやすくレクチャーする.

目次

  • 患者を末期腎不全にしないための CKD診療のコツ

    ―目次―

    I. CKDとはどんな病気ですか? 
     1.総論 CKDとはどんなもの
     2.糖尿病合併CKD患者は気をつけろ
     3.慢性腎炎の診療は難しくない
     4.腎代替療法をいつ、どのよう
        インフォームドコンセントするか
     ミニレクチャー ここが違うよCKD診療〜診療の常識・非常識〜

    II. 初期研修医でもこれだけは知っておきたい
     1. CKD患者の検査結果を解釈する・腎機能を評価する
     2.高血圧管理の考え方は? 
     ミニレクチャー 利尿薬の使い方は?
     ミニレクチャー RAS阻害薬の使い方のコツ
     3.CKD患者の糖尿病管理はここが違う 
     ミニレクチャー 糖尿病CKD患者の食事療法は高カロリー?
     4.食事・栄養評価はどうする? 
     5.CKD患者への投薬はここに気をつけろ! 
     ミニレクチャー 造影剤腎症を起こさないために 
     6.電解質がおかしい?  
     7.骨・ミネラル代謝異常にどう対処するか? 
     8.CKD患者の酸塩基平衡を理解しよう
     9.腎性貧血の管理はどうする?   
     10.難しくない体液量の評価

    III. 代表的な疾患別のマネジメント
     1.IgA腎症はどう治療する?
     2.ネフローゼ症候群はどう治療する?
     ミニレクチャー ネフローゼ症候群でない膜性腎症は
              どう治療するか?
     ミニレクチャー CKD患者の脂質異常治療薬の投与法は?
     3.腎硬化症をどう診断し、治療するか? 
     4.多発性嚢胞腎の診療チェックポイント
     ミニレクチャー CKD患者の高尿酸血症について  
     ミニレクチャー  血栓性微血管障害って何?

    IV. Step Up! 腎臓専門医をめざす後期研修医はこれができる
     1.急激に腎機能が低下した時にどうする?(AKI合併)
     2.虚血性心疾患を合併した場合はどうする?
     3.アミロイドーシスによるCKDをどう診るか?
     4.ループス腎炎によるCKDはどう治療するか?
     5.ANCA関連腎炎の患者をどう治療するか?
     6.腎移植患者の腎機能が低下した時の対策は?
     7.CKD患者の感染症をどう診療する?
     ミニレクチャー CKD患者の尿路感染症、何に気を付ける?
     8.妊娠したCKD患者をどう診るか? 
     9.高齢者のCKDをどう診るか? 
     ミニレクチャー 肝硬変を合併するCKD患者はどう対応する?

    付録:Further Readings

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. CKDとはどんな病気ですか ?

P.10 掲載の参考文献
1) National Kidney Foundation : K/DOQI Clinical Practice Guideline for Chronic Kidney Disease ; Evaluation, Classification and Stratification. Am J Kidny Dis 39 (Supple 1) : S1-S266, 2002.
2) Levey AS, et al. : The definition, classification, and prognosis of chronic kidney disease ; a KDIGO Controversies Conference report. Kidney Int 80 (1) : 17-28, 2011.
3) Imai E, et al. : Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13 (6) : 621-630, 2009.
4) Iseki K, et al. : Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRP in Okinawa, Japan. Am J Kidney Dis 44 : 806-814, 2004.
5) Imai E, et al. : Slower decline of glomerular filtration rate in the Japanese general population ; a longitudinal 10-year follow-up study. Hyperetens Res 31 : 433-441, 2008.
6) 日本腎臓学会編 : CKD診療ガイド 2012, 東京医学社, 2012.
7) Faul C, et al. : FGF23 induces left ventricular hypertrophy. J Clin Invest 121 (11) : 4393-408, 2011.
8) 二宮利治ほか : 久山町からみた慢性腎臓病 (CKD). 綜合臨牀 55 : 1248-1254, 2006.
9) Nakayama M, et al. : Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy ; the Gonryo study. Hypertens Res 34 : 1106-1110, 2011.
10) Hillege HL, et al. : Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 : 1777-1782, 2002.
11) Matsuo S, et al. : Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 53 (6) : 982-992, 2009.
P.19 掲載の参考文献
1) Parving HH, et al. : Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients ; a global perspective. Kidney Int 69 (11) : 2057-2063, 2006.
2) Yokoyama H, et al. : Microarubuminuria is common in japanese type 2 diabetic patients ; a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDMIO). Diabetes Care 30 (4) : 989-992, 2007.
3) Adler AI, et al. : Development and progression of nephropathy in type 2 diabetes ; the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 : 225-232, 2003.
4) de Zeeuw D, et al. : Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 : 921-927, 2004.
5) Araki S, et al. : Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 56 : 1727-1730, 2007.
6) Zoppini G, et al. : Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 7 : 401-408, 2012.
7) Haller H, et al. : Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364 : 907-917, 2011.
8) Makino H, et al. : Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30 : 1577-1578, 2007.
9) Shiga Microalbuminuria Reduction Tria (l SMART) Group : Reduction of microalbuminuria in patients with type 2 diabetes : the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 30 : 1581-1583,
10) Uzu T, et al. : Cerebral microvascular disease predicts renal failure in type 2 diabetes. J Am Soc Nephrol 21 : 520-526, 2010.
11) Uzu T, et al. : The effects of blood pressure control levels on the renoprotection of type 2 diabetic patients without overt proteinuria. J Am Soc Hypertens 6 : 124-131, 2012.
12) KDOQI : KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49 (Suppl 2) : S12-154, 2007.
13) de Mast Q, Beutler JJ : The prevalence of atherosclerotic renal artery stenosis in risk groups ; a systematic literature review. J Hypertens 27 : 1333-1340, 2009.
P.30 掲載の参考文献
1) 日本腎臓学会編 : CKD診療科ガイド 2012. 東京医学社, 2012.
2) De Santo NG, et al. : Phase contrast microscopy of the urine sediment for the diagnosis of glomerular and non-glomerular bleeding-data in children and adults with normal creatinine clearance. Nephron 45 : 35-39, 1987.
3) Iseki K, et al. : Proteinuria and the risk of developing end-stage rend disease. Kidney Int 63 : 1468-1474, 2003.
4) 厚生労働科学研究費補助金難治性疾患克服研究事業進行性腎障害に関する調査研究班報告 : IgA腎症分科会 IgA腎症診療指針 第3版. 日腎会誌 53 (2) : 123-135, 2011.
P.34 掲載の参考文献
1) 日本腎臓学会, 日本透析医学会, 日本移植学会, 日本臨床腎移植学会編 : 腎不全 治療選択とその実際 2012年版. www.jsn.or.jp/jsn_new/iryou/kaiin/free/primers/pdf/sentaku_book.pdf
2) Yamagata K, et al. ; Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy : Ideal timing and predialysis nephrology care duration for dialysis initiation ; from analysis of Japanese dialysis initiation survey. Ther Apher Dial 16 (1) : 54-62, 2012.
3) 日本透析医学会編 : 2009年版 腹膜透析ガイドライン. 透析会誌 42 (4) : 285-315, 2009.
4) Cooper BA, et al. : A randomized control trial of early versus late initiation of dialysis. N Engl J Med 363 : 609-619, 2010.
5) Rosansky SJ, et al. : Early start of hemodialysis may be harmful. Arch Intern Med 171 (5) : 396-403, 2011.
P.38 掲載の参考文献
1) Yamagata K, et al. : Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 12 : 1-8, 2008.
2) Imai E, et al. : Slower decline of glomerular filtration rate in the Japanese general population ; A longitudinal 10-year follow-up study. Hypertens Res 31 : 433-441, 2008.
3) Iseki K, et al. : Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63 : 1468-1474, 2003.
4) 渡辺毅ほか : 慢性腎疾患のスクリーニングと診断. 日医雑誌 134 : 2330-2334, 2006.
5) Yamagata K, et al. : A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol 45 : 281-288, 1996.
6) 日本腎臓学会編 : CKDにおける薬物治療の注意 CKD診療ガイドライン 2012. pp.94-99, 東京医学社, 2012.
7) Shlipak MG, et al. : Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 : 2049-2060, 2005.
8) Horio M, et al. : Performance of serum cystatin C versus serum creatinine as a marker of glomerular filtration rate as measured by inulin renal clearance. Clin Exp Nephrol 15 : 868-876, 2011.
9) Stevens LA, et al. : Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 75 : 652-660, 2009.

II. 初期研修医でもこれだけは知っておきたい

P.49 掲載の参考文献
1) Horio M, et al. ; Japanese Equation for Estimating GFR : Simple sampling strategy for measuring inulin renal clearance. Clin Exp Nephrol 13 (1) : 50-54, 2009.
2) Horio M, et al. : Comparison of a simple and a standard method for inulin renal clearance. Clin Exp Nephrol 14 (5) : 427-430, 2010.
3) Orita Y, et al. : Estimation of glomerular filtration rate by inulin clearance ; Comparison with creatinine clearance. Jpn J Nephrol 47 : 804-812, 2005.
4) Horio M, et al. : Performance of serum cystatin C versus serum creatinine as a marker of glomerular filtration rate as measured by inulin renal clearance. Clin Exp Nephrol 15 (6) : 868-876, 2011.
5) Matsuo S, et al. ; Collaborators developing the Japanese equation for estimated GFR : Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53 (6) : 982-992, 2009.
6) Horio M, et al. : behalf of the collaborators developing the Japanese equation for estimated GFR : GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. in press
7) 日本腎臓学会編 : CKD診療ガイド 2012. 東京医学社, 2012.
P.57 掲載の参考文献
1) Bakris GL, et al. : Preserving renal function in adults with hypertension and diabetes ; a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36 : 646-661, 2000.
2) Ogihara T, et al. : Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications ; a sub-analysis of the CASE-J trial. Hypertens Res 32 : 248-254, 2009.
3) Turnbull F, et al. ; Blood Pressure Lowering Treatment Trialists Collaboration : Effects of different blood-pressure-lowering regimens on major cardiovascular events ; results of prospectively-disigned overviews of randomised trials. Lancet 362 : 1527-1535, 2003.
4) 日本腎臓学会編 : CKD診療ガイド 2012. 東京医学社, 2012.
5) Ohkubo T, et al. : Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 46 : 508-515, 2005.
6) Asayama K, et al. : Prediction of stroke by home "morning" versus "evening" blood pressure values ; the Ohasama study. Hypertension 48 : 737-743, 2006.
7) Ohkubo T, et al. : Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure ; the Ohasama stud. J Hypertens 20 : 2183-2189, 2002.
8) Terawaki H, et al. : Masked hypertension determined by self-measured blood pressure at home and chronic kidney disease in the Japanese general population ; the Ohasama study. Hypertens Res 31 : 2129-2135, 2008.
9) Ohkubo T, et al. : Relation between nocturnal decline in blood pressure and mortality, The Ohasama study. Am J Hypertens 10 : 1201-1207, 1997.
10) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009. pp.8-13, 37-45, ライフサイエンス出版, 2009
11) Ruggenenti P, Remuzzi G : Proteinuria ; Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 5 : 436-437, 2009.
12) Ruggenenti P, et al. : Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 : 1941-1951, 2004.
13) Haller H, et al. : Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364 : 907-917, 2011.
14) Shiga Microalbuminuria Reduction Trial (SMART) Group : Reduction of microalbuminuria in patients with type 2 diabetes ; the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 30 : 1581-1583, 2007.
15) Makino H, et al. : Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30 : 1577-1578, 2007.
16) Holtkamp FA, et al. : Albuminuria and blood pressure, independent target for cardioprotective theraphy in patients with diabetes and nephropathy ; a post hoc analysis of the combined RENNAL and IDNT trials. Eur Heart J 32 : 1493-1499, 2011.
17) Parving HH, et al. : Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358 : 2433-2446, 2008.
18) Bakris GL, et al. : Preserving renal function in adults with hypertension and diabetes ; a consensus approch. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36 : 646-661, 2000.
19) Tamura K, et al. : Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease. Am J Cardiovasc Dis 1 : 236-243, 2011.
20) Jamerson K, et al. : Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 : 2417-2428, 2008.
21) Webb AJ, et al. : Effects of antihypertensive-drug class on interindividual in blood pressure and risk of stroke ; a systematic review and meta-analysis. Lancet 375 : 906-915, 2010.
22) Fujita T, et al. : Antiproteinuric effect of the calcium channel blocker cilndipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 72 : 1543-1549, 2007.
23) Navaneethan SD, et al. : Aldosterone antagonists for preventing the progression of chronic kidney disease ; a systematic review and meta-analysis. Clin J Am Soc Nephrol 4 : 542-551, 2009.
24) Appel RG, et al. : Renovascular disease in older patients beginning renal replacement therapy. Kidney Int 48 : 171-176, 1995.
P.61 掲載の参考文献
1) 谷口茂夫 : 考える腎臓病学. メディカル・サイエンス・インターナショナル, 2011.
2) Williams B, et al. ; British Hypertension Society : Guidelines for management of hypertension ; report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18 : 139-185, 2004.
3) Stern SDC, et al. : Symptom to Diagnosis An evidence-based Guide, 2nd ed. pp.327-345, McGraw-Hill, 2010.
4) Robert W, Schrier Ed : Renal and Electrolyte Disorders, 7th ed. Lippincott Williams& Wilkins, 2010.
5) Kaplan NM, Victor RG : Kaplan's Clinical Hypertension, 7th ed. Lippincott Williams & Wilkins, 2010.
6) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009. ライフサイエンス出版, 2009.
P.64 掲載の参考文献
1) 日本腎臓学会 : CKD診療ガイド 2012. 東京医学社, 2012.
2) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009. ライフサイエンス出版, 2009.
3) Bakris GL,Weir MR : Angiotensin-converting enzyme inhibitor-associated elevation in serum creatinine. Is this a cause for concern? Arch Intern Med 160 : 685-693, 2000.
4) 黒川清, 伊藤貞嘉 : 糖尿病を合併した高血圧患者の治療はどうあるべきか. 医薬ジャーナル 38 : 558-565, 2002.
5) Anand IS, et al. : Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure ; results from Val-HeFT. Circulation 112 : 1121-1127, 2005.
6) Meur YL, et al. : Plasma levels and metabolism of AcSDKP in patients with chronic renal failure ; relationship with erythropoietin requirements. Am J Kidney Dis 38 : 510-517, 2001.
P.71 掲載の参考文献
1) Ohkubo Y, et al. : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanease patients with non-insulin-dependent diabetes mellitus ; a randomized prospective 6-year study. Diabetes Res Clin Pract 28 : 103-117, 1995.
2) Fioretto P, et al. : Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339 : 69-75, 1998.
3) Coppelli A, et al. : Disappearance of nephrotic syndrome in type 1 diabetic patients following pancreas transplant alone. Transplantation 81 : 1067-1068, 2006.
4) Fukuoka K, et al. : Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology 13 : 278-283, 2008.
5) Okada T, et al. : Association between markers of glycemic control, cardiovascular and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 46 : 807-814, 2007.
7) Duckworth W, et al. : Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 : 129-139, 2009.
8) Araki S, et al. : Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54 : 2983-2987, 2005.
9) Araki S, et al. : Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 56 : 1727-1730, 2007.
P.74 掲載の参考文献
1) 糖尿病性腎症に関する合同委員会報告. 日腎会誌 44 : 87-101, 2002.
2) 日本糖尿病学会編 : 糖尿病治療ガイド 2012-2013. 文光堂, 2012.
3) 日本腎臓学会編 : エビデンスに基づくCKD診療ガイドライン 2009. 東京医学社, 2009.
4) Morales E, et al. : Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 41 : 319-327, 2003.
P.80 掲載の参考文献
1) Sacks FM, et al. : Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (dash) diet. Dash-sodium collaborative research group. N Engl J Med 344 : 3-10, 2001.
2) Vegter S, et al. : Sodium intake, ace inhibition, and progression to esrd. J Am Soc Nephrol 23 : 165-173, 2012.
3) Imai E, et al. : Validation of the equations for estimating daily sodium excretion from spot urine in patients with chronic kidney disease. Clin Exp Nephrol 15 : 861-867, 2011.
4) Stenvinkel P, et al. : Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (mia syndrome). Nephrol Dial Transplant 15 : 953-960, 2000.
5) Honda H, et al. : Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr 86 : 633-638, 2007.
6) Fouque D, et al. : A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73 : 391-398, 2008.
P.94 掲載の参考文献
1) Zhang Y, et al. : Assessment of the impact of renal impairment on systemic exposure of new molecular entities ; evaluation of recent new drug applications. Clin Pharmacol Ther 85 : 305-311, 2009.
3) Olyaei AJ, Steffl JL : A quantitative approach to drug dosing in chronic kidney disease. Blood Purif 31 : 138-145, 2011.
4) Lam YW, et al. : Principles of drug administration in renal insufficiency. Clin Pharmacokinet 32 : 30-57, 1997.
5) Nolin TD, et al. : Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 42 : 906-25, 2003.
6) Matzke GR, et al. : Renal Disaese. Clinical Drug Data, 11th ed (ed by Smith K, et al.). pp.1123-1131, McGraw-Hill Medical, Ohio, 2010.
7) Nicolas HG, Holford. Pharmacokinetics & Pharmacodynamics : Rational Dosing & the Time Course of Drug Action. Basic and clinical pharmacology, 11th ed (ed by Katzung GB, et al.). pp.37-51, McGraw-Hill Medical, Ohio, 2008.
8) Nolin TD : Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens 17 : 555-559, 2008.
9) Verbeeck RK, Musuamba FT : Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65 : 757-773, 2009.
10) Matzke GR, et al. : Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease ; Improving Global Outcomes (KDIGO). Kidney Int 80 : 1122-1137, 2011.
11) 大園恵幸ほか : 薬剤性腎障害. 日本臨牀 60 : 493-500, 2002.
P.97 掲載の参考文献
1) 日本腎臓学会編 : CKD診療ガイド 2012. 東京医学社, 2012.
2) 日本腎臓学会, 日本医学放射線学会, 日本循環器学会編著 : 腎障害患者におけるヨード造影剤使用に関するガイドライン 2012. 東京医学社, 2012.
3) 日本腎臓学会 : 腎障害患者におけるガドリニウム造影剤使用に関するガイドライン 第2版. 2009. http://www.jsn.or.jp/jsn_new/news/guideline_nsf_090902.pdf
P.106 掲載の参考文献
1) Bricker NS : Observations on the concentrating and diluting mechanisms of the diseased kidney. J Clin Invest 38 : 516-523, 1959.
2) Huang CL : Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 18 : 2649-2652, 2007.
3) Shimada T, Hasegawa H : FGF-23 is a potent regular of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19 : 429-435, 2004.
4) Kanbay M, Goldsmith D : Magnesium in chronic kidney disease ; challenges and opportunities. Blood Purif 29 : 280-292, 2010.
P.112 掲載の参考文献
1) KDIGO Clinical practice Guideline for the Diagnosis, Evaluation, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 76 (Suppl 113) : S1-S113, 2009
2) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 (4) : 301-356, 2012.
3) Moe S, et al. ; Kidney Disease ; Improving Global Outcome (KDIGO) : Definition, evaluation, and classification of renal osteodystrophy ; a position statement from Kidney Disease ; Improving Global Outcome (KDIGO). Kidney Int 69 : 1945-1953, 2006
4) National Kidney Foundation : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney failure. Am J Kidney Dis 42 (Suppl 3) : S1-S201, 2003.
P.118 掲載の参考文献
1) Warnock DG : Uremic acidosis. Kidney Int 34 (2) : 278-87, 1988.
2) Caravaca F, et al. : Metabolic acidosis in advanced renal failure ; differences between diabetic and nondiabetic patients. Am J Kidney Dis 33 (5) : 892, 1999.
3) Kraut JA, Madias NE : Serum anion gap ; its uses and limitations in clinical medicine. Clin J Am Soc Nephrol 2 (1) : 162-174, 2007.
4) Feldman M, et al. : Influence of hypoalbuminemia or hyperalbuminemia on the serum anion gap. J Lab Clin Med 146 (6) : 317-320, 2005.
5) Menon V, et al. : Serum bicarbonate and long-term outcomes in CKD. Am J Kidney Dis 56 (5) : 907-914, 2010.
6) de Brito-Ashurst I, et al. : Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20 (9) : 2075-2084, 2009.
7) Phisitkul S, et al. : Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 77 (7) : 617-623, 2010.
8) Mahajan A, et al. : Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 78 (3) : 303-309, 2010.
9) Nath KA, et al. : Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 76 (2) : 667-675, 1985.
10) Wesson DE, et al. : Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol 300 (4) : F830-837, 2011.
11) Bailey JL, et al. : The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent Ubiquitin-proteasome pathway. J Clin Invest 97 (6) : 1447-1453, 1996.
12) Williams B, et al. : Metabolic acidosis and skeletal muscle adaptation to low protein diets in chronic uremia. Kidney Int 40 (4) : 779-786, 1991.
13) Bushinsky DA : The contribution of acidosis to renal osteodystrophy. Kidney Int 47 (6) : 1816-1832, 1995.
14) Lefebvre A, et al. : Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36 (6) : 1112-1118, 1989.
15) Mathur RP, et al. : Effects of correction of metabolic acidosis on blood urea and bone metabolism in patients with mild to moderate chronic kidney disease ; a prospective randomized single blind controlled trial. Ren Fail 28 (1) : 1-5, 2006.
16) Kraut JA, Madias NE : Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 26 (1) : 19-28, 2011.
17) National Kidney Foundation : K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3) : S1-S201, 2003.
18) Mauro LS, et al. : Impact of oral bases on aluminum absorption. Am J Ther 8 (1) : 21-25, 2001.
19) Weinberger MH : Sodium chloride and blood pressure. N Engl J Med 317 (17) : 1084-1086, 1987
P.123 掲載の参考文献
1) Bernhardt WM, et al. : Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21 (12) : 2151-2156, 2010.
2) Levin A, et al. : Left ventricular mass index increase in early renal disease ; impact of decline in hemoglobin. Am J Kidney Dis 34 (1) : 125-134, 1999.
3) Silverberg DS, et al. : The cardio-renal anemia syndrome ; dose it exist? Nephrol Dial Transplant 18 (Supple 8) : 2003.
4) Drueke TB, et al. : Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (20) : 2071-2084, 2006.
5) Singh AK, et al. : Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (20) : 2085-2098, 2006.
6) Pfeffer MA, et al. ; A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (21) : 2019-2032, 2009.
7) 日本腎臓学会編 : エビデンスに基づくCKD診療ガイドライン 2009. 東京医学社, 2009.
P.130 掲載の参考文献
1) 飯島毅彦 : 体液量をいかに把握するか? 循環血液量の位置づけ. 体液・代謝管理 25 : 21-26, 2009.
2) McGee S, et al. : Is this patient hypovolemia? JAMA 281 : 1022-1029, 1999.
3) Valtin H, Schafer JA : The body fluid compartments. Renal Function, 3rd ed. pp.17-39, Little, Brown, Boston, 1995.
4) Ando Y, et al. : The inferior vena cava diameter as a marker of dry weight in chronic hemodialyzed patients. Artif Organs 19 : 1237-1242, 1995.
5) 安藤康宏 : Dry weight 設定法の改良. 日本臨牀 62 (増刊 5) : 189-195, 2004,
6) 安藤康宏 : 体液量評価法. 今日の治療 9 : 23-26, 2001.
7) Luft FC, et al. : Cardiopulmonary effects of volume expansion in man ; radiographic manifestations. Am J Roentogenol 144 : 289-293, 1985.
8) 佐々木信博ほか : 生体電気インピーダンス (BIA) 法によるDW 設定基準 高精度体成分分析装置 (InBody S20) による浮腫値 (ECW/TBW) での検討. 日本透析医学会雑誌 : 723-730, 2008
9) Morishita Y, et al. : Comparison of markers of circulating blood volume in hemodialysis patients. Clin Exp Nephrol 9 : 233-237, 2005.

III. 代表的な疾患別のマネジメント

P.137 掲載の参考文献
1) Praga M, et al. : Treatment of IgA nephropathy with ACE inhibitors ; a randomized and controlled trial. J Am Soc Nephrol 14 : 1578-1583, 2003.
2) Woo KT, et al. : Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis. Cell Mol Immunol 4 : 227-232, 2007.
3) Reid S, et al. : Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011 Mar 16 ; (3) : CD003962.
5) Pozzi C, et al. : Corticosteroids in IgA nephropathy ; a randomised controlled trial. Lancet 353 : 883-887, 1999.
6) Lv J, et al. : Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy ; a randomized controlled trial. Am J Kidney Dis 53 : 26-32, 2009.
7) Manno C, et al. : Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24 : 3694-3701, 2009.
8) Hotta O, et al. : Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 38 : 736-743, 2001.
9) Ballardie FW, Roberts IS : Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13 : 142-148, 2002.
10) Pozzi C, et al. : Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21 : 1783-1790, 2010.
11) Donadio JV Jr, et al. : A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 331 : 1194-1199, 1994.
P.145 掲載の参考文献
1) 厚生労働省難治性疾患克服研究事業進行性腎障害に関する調査研究班難治性ネフローゼ症候群分科会編 : ネフローゼ症候群診療指針 [完全版]. 東京医学社, 2012.
2) 斉藤喬雄ほか難治性ネフローゼ症候群の治療に関する研究. 進行性腎障害に関する調査研究 平成21年度総括・分担研究報告書 (松尾清一主任研究者). pp.99-109, 2010.
3) Shiiki H, et al. : Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 65 : 1400-1407, 2004.
P.148 掲載の参考文献
1) Hladunewich MA, et al. : The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 4 : 1417-1422, 2009.
2) Polanco N, et al. : Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21 : 697-704, 2010.
3) Lionaki S, et al. : Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 7 : 43, 2012.
P.151 掲載の参考文献
1) Shepherd J, et al. : Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease ; the TNT (Treating to New Targets) study. J Am Coll Cardiol 51 (15) : 1448-1454, 2008.
2) Nakamura H, et al. : Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 206 (2) : 512-517, 2009.
3) Sandhu S, et al. : Statins for improving renal outcomes ; a meta-analysis. J Am Soc Nephrol 17 (7) : 2006-2016, 2006.
4) Navaneethan SD, et al. : HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2 : CD007784, 2009.
5) Strippoli GF, et al. : Effects of statins in patients with chronic kidney disease ; meta-analysis and meta-regression of randomised controlled trials. Bmj 336 (7645) : 645-651, 2008.
6) Bianchi S, et al. : A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41 (3) : 565-570, 2003.
7) Bianchi S, et al. : Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis 55 (4) : 671-681, 2010.
8) Shepherd J, et al. : Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease ; the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2 (6) : 1131-1139, 2007.
9) Colhoun HM, et al. : Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes ; an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 54 (5) : 810-819, 2009.
10) Kimura K, et al. : Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb 17 (6) : 601-609, 2010.
11) Ruggenenti P, et al. : Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade ; the ESPLANADE trial. Clin J Am Soc Nephrol 5 (11) : 1928-1938, 2010.
12) Rahman M, et al. : Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care : a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Tria (l ALLHAT). Am J Kidney Dis 52 (3) : 412-424, 2008.
13) Huskey J, et al. : Effect of simvastatin on kidney function loss in patients with coronary heart disease ; findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis 205 (1) : 202-206, 2009.
14) Lemos PA, et al. : Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol 95 (4) : 445-451, 2005.
15) Fassett RG, et al. : Effect of atorvastatin on kidney function in chronic kidney disease ; a randomised double-blind placebo-controlled trial. Atherosclerosis 213 (1) : 218-224, 2010.
16) Landray M, et al. : The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study ; a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47 (3) : 385-395, 2006.
17) Baigent C, et al. : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) ; a randomised placebo-controlled trial. Lancet 377 (9784) : 2181-2192, 2011.
18) Renke M, et al. : Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease-placebo controlled, randomized, cross-over study. Acta Biochim Pol 57 (4) : 547-552, 2010.
19) Nakamura T, et al. : Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev 3 (5) : 304-307, 2010.
20) Inoue T, et al. : Potential benefit of statin therapy for dyslipidemia with chronic kidney disease ; Fluvastatin Renal Evaluation Tria (l FRET). Intern Med 50 (12) : 1273-1278, 2011.
21) Epstein M, Campese VM : Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 45 (1) : 2-14, 2005.
22) Krane V, Wanner C : Statins, inflammation and kidney disease. Nat Rev Nephrol 7 (7) : 385-397, 2011.
23) Ray KK, Cannon CP : The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 46 (8) : 1425-1433, 2005.
24) Keech A, et al. : Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) ; randomised controlled trial. Lancet 366 (9500) : 1849-1861, 2005.
25) 日本腎臓学会編 : CKD診療ガイド 2012. 東京医学社, 2012.
26) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン 2012年版. 2012.
27) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44 (5) : 337-425, 2011.
P.165 掲載の参考文献
1) Mochizuki T, et al. : Autosomal dominant polycystic kidney disease ; recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2012 Nov 29.
2) Grantham JJ, et al. : Volume progression in autosomal dominant polycystic kidney disease ; the major determining clinical outcomes. Clin J Am Soc Nephrol 1 : 148-157, 2006.
3) Chapman AB, et al. : Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 7 : 479-486, 2012.
4) Sallee M, et al. : Cyst Infections in Patients with Autosomal Dominant Polycystic Kidney Disease Clin J Am Soc Nephrol 4 : 1183-1189, 2009.
5) Torres VE, et al. : Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367 : 2407-2418, 2012.
P.168 掲載の参考文献
1) Feig DI, et al. : Uric acid and cardiovascular risk. N Engl J Med 359 (17) : 1811-1821, 2008.
2) Freedman DS, et al. : Relation of serum uric acid to mortality and ischemic heart disease ; The NHANES I epidemiologic follow-up study. Am J Epidemiol 141 : 637-644, 1995.
3) Fang J, Alderman MH : Serum uric acid and cardiovascular mortality ; The NHANES I epidemiologic follow-up study, 1971-1992 ; National Health and Nutrition Examination Survey. JAMA 283 : 2404-2410, 2000.
4) 日本痛風・核酸代謝学会ガイドライン改訂委員会編 : 2010年度高尿酸血症・痛風の治療ガイドライン 第2版. メディカルビュー社, 2010.
5) Goicoechea M, et al. : Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5 : 1388-1393, 2010.
6) 内田俊也 : 慢性腎臓病 (CKD) に合併する高尿酸血症に対するベンズブロマロンの臨床的有用性の検討. 医と薬学 57 : 879-882, 2007.
P.172 掲載の参考文献
1) Besbas N, et al. ; European Paediatric Research Group for HUS : A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70 : 423-431, 2006.
2) Milford D, et al. : Haemolytic uraemic syndromes in the British Isles 1985-8 ; association with verocytotoxin producing Escherichia coli. Part 1 ; clinical and epidemiological aspects. Arch Dis Child 65 : 716-721, 1990.
3) Rock GA, et al. : Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. A Candadian apheresis study group. N Engl J Med 325 : 393-397, 1991.
4) Zheng X, et al. : Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 138 : 105-108, 2003.

IV. Step Up ! 腎臓専門医を目指す後期研修医はこれができる

P.181 掲載の参考文献
1) Kidney Disease Improving Global Outcomes : KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2 (Suppl) : 1-138, 2012.
2) Hsu CY, et al. : The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 74 : 101-107, 2008.
3) Abuelo JG : Normotensive ischemic acute renal failure. N Engl J Med 357 (8) : 797-805, 2007.
4) Arendshorst WJ, et al. : Renal circulation and glomerular hemodynamics. Diseases of the Kidney and Urinary Tract, 8th ed (Schrier RW ed). pp.54-95, Wolters Kluwer, 2007.
5) Wu VC, et al. : Acute-on-chronic kidney injury at hospital discharge is associated with long-term dialysis and mortality. Kidney Int 80 (11) : 1222-1230, 2011.
6) Waikar SS, Bonventre JV : Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 20 (3) : 672-679, 2009.
7) Friedrich JO, et al. : Meta-analysis ; low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142 (7) : 510-524, 2005.
8) Bellomo R, et al. : Vasoactive drugs and acute kidney injury. Crit Care Med 36 (4 Suppl) : S179-186, 2008.
9) De Backer D, et al. : Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 (9) : 779-789, 2010.
10) Liu KD, et al. : Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 1 : 915-919, 2006.
P.187 掲載の参考文献
1) 二宮利治ほか : Longtudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. 綜合臨牀 55 : 1248-1254, 2006.
2) Keith DS, et al. : CKD診療ガイド 2009. Arch Intern Med 164 (6) : 659, 2004.
3) K/DOQI Clinical Practice Guidelines : CKD診療ガイド 2009. Am J Kidney Dis 43 (Suppl 1) : S1-S290, 2004.
4) K/DOQI clinic al practice guidelines. Am J Kidney Dis 2003.
5) 日本透析医学会 : 慢性透析患者に関する基礎集計. 図説わが国の慢性透析療法の現況. http : docs.jsdt.or.jp
6) Alonso A, et al. : Chronic kidney disease is associated with the incidence of atrial fibrillation ; the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 123 : 2946-2953, 2011.
7) Szczech LA, et al. : Outocomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation 105 : 2253-2258, 2002.
8) Miyagi M, Ishii H : Impact of renal function on coronary plaque composition. Nephrol Dial transplant 25 : 175-181, 2010.
9) The TNT (Treating to New Targets) Study : Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease ; the TNT (Treating to New Target) study. J Am Coll Cardiol 51 : 1448-1454, 2008.
10) Michael J, et al. : Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD. Am J Kidney Dis 53 : 741-750, 2009.
P.194 掲載の参考文献
1) アミロイドーシスに関する調査研究班 (研究代表者山田正仁) : アミロイドーシス診療ガイドライン 2010. 2010.
2) Dember LM : Amyloidosis-associated kidney disease. J Am Soc Nephrol 17 : 3458-3471, 2006.
3) Gallo G, et al. : Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 145 : 526-530, 1994.
4) Nishi S, et al. : New advances in renal amyloidosis. Clin Exp Nephrol 12 : 93-101, 2008.
5) Dispenzieri A, et al. : International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23 (2) : 215-224, 2009.
P.204 掲載の参考文献
1) Tan EM, et al. : The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 : 1271-1277, 1982.
2) Hochberg MC : Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 : 1725, 1997.
3) Weening JJ, et al. : The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65 : 521-530, 2004.
4) 長田道夫 : ループス腎炎病理診断の新しい分類 ; Isn/rps 2003年改訂分類の要点と診断マニュアル. 日腎会誌 46 : 383-395, 2004.
5) Hahn BH, et al. : American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 64 : 797-808, 2012.
6) Appel GB, et al. : Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20 : 1103-1112, 2009.
7) Houssiau FA, et al. : The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69 : 61-64, 2010.
8) Cortes-Hernandez J, et al. : Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 25 : 3939-3948, 2010.
9) Boletis JN, et al. : Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354 : 569-570, 1999.
10) Karim MY, et al. : Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not! Rheumatology (Oxford) 48 : 332-341, 2009.
11) Houssiau FA : Therapy of lupus nephritis : Lessons learned from clinical research and daily care of patients. Arthritis Res Ther 14 : 202, 2012.
12) 高崎芳成全身性エリテマトーデス・ループス腎炎の分子標的療法. 日腎会誌 54 : 598-602, 2012.
13) Suzuki K, et al. : Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus. Arthriti Rheum 34 : 1546-1552, 1991.
14) Gaubitz M, et al. : Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 11 : 495-501, 1998.
15) Bono L, et al. : The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 92 : 211-218, 1999.
16) 日本透析医学会 : わが国の慢性透析療法の現況 2011年12月31日現在. 2012.
P.212 掲載の参考文献
1) 急速進行性糸球体腎炎診療指針作成合同委員会 : 急速進行性腎炎症候群の診療指針. 日腎会誌 44 : 55-82, 2002.
2) 進行性腎障害に関する調査研究班急速進行性腎炎症候群分科会 : 急速進行性腎炎症候群の診療指針 第2版. 日腎会誌 53 : 509-555, 2011.
3) Berden AE, et al. : Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21 : 1628-1636, 2010.
4) Mukhtyar C, et al. : Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68 : 1827-1832, 2009.
5) Exley AR, et al. : Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitoides. Arthritis Rheum 40 : 371-380, 1997.
6) http://www.vasculitis.org/
7) Lapraik C, et al. : BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 46 : 1615-1616, 2007.
8) Jayne D, et al. : A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 : 36-44, 2003.
9) De Groot K, et al. : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med 150 : 670-680, 2009.
10) Jayne DRW, et al. : Randomized trial of plasma exchange or high-dosage methylredonisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 : 2180-2188, 2007.
11) Jones RB, et al. : Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363 : 211-220, 2010.
P.214 掲載の参考文献
1) 田崎正行ほか : 移植 45 465-472, 2010.
2) 東間紘, 高橋公太編著 : 腎移植ハンドブック. 中外医学社, 2000.
3) 難波行臣ほか : 腎と透析 60 : 481-485, 2006.
4) 両角國男ほか : 今日の移植 16 : 379-365, 2003.
5) 高橋公太編 : 腎移植のすべて, メジカルビュー社, 2009.
P.219 掲載の参考文献
1) Dalrymple LS, Go AS : Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 3 (5) : 1487-1493, 2008.
2) 青木眞 : レジデントのための感染症診療マニュアル 第2版. 医学書院, 2009.
3) Choi HK, et al. : Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 43 (1) : 226-231, 2000.
4) Dalrymple LS, et al. : The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 59 (3) : 356-363, 2012.
5) James MT, et al. : CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 54 (1) : 24-32, 2009.
6) 大石和久 : どうコントロールするか透析患者の感染症 ワクチン接種 インフルエンザワクチン, HBVワクチン, 肺炎球菌ワクチン. 臨床透析 25 (1) : 127-133, 2009.
7) DaRoza G, et al. : Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization ; earlier is better. Am J Kidney Dis 42 (6) : 1184-1192, 2003.
8) Foley RN : Infections in patients with chronic kidney disease. Infect Dis Clin North Am 21 (3) : 659-672, viii. 2007.
9) Rho YH, et al. : Risk factors for pseudogout in the general population. Rheumatology (Oxford) 51 (11) : 2070-2074, 2012.
P.229 掲載の参考文献
1) Piccoli GB, et al. : Pregnancy and chronic kidney disease ; A challenge in all CKD stages. Clin J Am Soc Nephrol 5 (5) : 844-855, 2010.
2) Nevis IF, et al. : Pregnancy outcomes in women with chronic kidney disease ; a systematic review. Clin J Am Soc Nephrol 6 (11) : 2587-2598, 2011.
3) 日本妊娠高血圧学会編 : 妊娠高血圧症候群 (PIH) 管理ガイドライン 2009. メディカルビュー社, 2009.
4) 日本腎臓学会腎疾患患者の妊娠に関するガイドライン作成小委員会 : 腎疾患患者の妊娠に関する診療の手引き 平成19年1月修正案
P.234 掲載の参考文献
1) Imai E, et al. : Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13 : 621-630, 2009.
2) Iseki K, et al. : Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 49 : 800-805, 1996.
3) O'Hare AM, et al. : Mortality risk stratification in chronic kidney disease ; one size for all ages? J Am Soc Nephrol 17 : 846-853, 2006.
4) Glassock RJ, Winearls C : Screening for CKD with eGFR ; doubts and dangers. Clin J Am Soc Nephrol 3 : 1563-1568, 2008.
5) 日本腎臓学会編 : CKD診療ガイド 2012. 東京医学社, 2012.
6) Oates DJ, et al. : Blood pressure and survival in the oldest old. Am J Geriat Soc 55 : 383-388, 2007.
7) Denardo SJ, et al. : Blood pressure and outcomes in very old hypertensive coronary artery disease patients ; an INVEST substudy. Am J Med 123 : 719-726, 2010.
P.237 掲載の参考文献
1) Gluud LL, et al. : Systematic review of randomized tria1s on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 51 : 576-584, 2010.
2) Pache I, Bilodeau M : Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 21 : 525-529, 2005.
3) 日本消化器病学会編 : 肝硬変合併症の診断・治療腹水. 肝硬変診療ガイドライン. pp.116-149, 2010.
4) Inoue N, et al. : Treatment of intractable ascites by continuous reinfusion of the sterilized, cell-free and concentrated ascitic fluid. Trans Am Soc Artif Intern Organs 23 : 699-702, 1977.
5) 南部かおりほか : 肝硬変に伴う難治性腹水治療におけるDenver Peritoneovenous shunt の有用性の検討. 肝臓 37 : 723-730, 1996.
6) Spahr L, et al. : Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 90 : 1169-1171, 1995.

付録 : Further Readings

P.240 掲載の参考文献
(1) KDIGO Clinical Practice Guideline for Glomerulonephritis Kidney International volume 2 | issue 2 | JUNE 2012 209 Chapter 10 : Immunoglobulin A nephropathy
(1) 日本腎臓学会編 : CKD診療ガイド 2012 : 東京医学社 : 2012
(2) 厚生労働省科学研究費補助金難治性疾患克服研究事業 : ANCA関連血管炎の診療ガイドライン http://minds.jcqhc.or.jp/n/med/4/med0094/G0000332/0001 : 2011
(2) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2009 : ライフサイエンス出版 : 2009
(3) 日本腎臓学会編 : エビデンスに基づくCKD診療ガイドライン 2009 : 東京医学社 : 2009
(4) Williams B, et al. ; British Hypertension Society : Guidelines for management of hypertension ; report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18 : 139-185. : 2004
(5) Stern SDC, et al. : Symptom to Diagnosis An evidence-based Guide, 2nd ed.
(6) Schrier RW 著, 南学正臣, 奥田俊洋監訳 : シュライアー腎臓病と病態生理 : メディカル・サイエンス・インターナショナル : 2011
(7) American Pharmacists Association : Drug Information Handbook, 22nd ed (Lexi-Comp) : Lexi Comp : 2013
(8) Aileen Currie : The Renal Drug Handbook, 3rd ed : Radcliffe Medical Press : 2008
(9) David N, et al. : The Sanford Guide to Antimicrobial Therapy, 2012 (Sanford Guide), 42th ed : Antimicrobial Therapy : 2012
(10) Katzung BG, et al. : Basic and Clinical Pharmacology, McGrawHill Medical, 12th ed : McGraw-Hill Medical : 2011
(11) 柴垣有吾 : より理解を深める! 体液電解質異常と輸液 3版 : 中外医学社 : 2007
(12) 柴垣有吾 : 保存期腎不全の診かた : 中外医学社 : 2007
(13) 今井裕一 : 酸塩基平衡, 水・電解質が好きになる : 羊土社 : 2007
(14) 栗山哲 : これでわかる 腎性貧血の診かたと治療 : 南江堂 : 2010
(15) Valtin H, Schafer JA : Renal Function, 3rd ed : Little, Brown : 1995
(16) 浅野泰監修, 草野英二ほか編 : 腎臓内科診療マニュアル : 日本医学館 : 2010
(17) IgA腎症診療指針 第3版. 日腎会誌 53 (2) : 123-135 : 2011
(18) 厚生労働省難治性疾患克服研究事業進行性腎障害に関する調査研究班難治性ネフローゼ症候群分科会編 : ネフローゼ症候群診療指針 [完全版] : 東京医学社 : 2012
(19) 松尾清一監修, 堀江重郎編 : 進行性腎障害診療指針シリーズ ; 多発性嚢胞腎 診療ガイド Q&A : 診断と治療社 : 2011
(20) Dember LM : Modern treatment of amyloidosis ; unresolved questions. J Am Soc Nephrol 20 : 469-472 : American Society of Nephrology : 2009
(21) Lahita RG et al. : Sysetmic lupus erythematosus, 5th ed : Elsevier : 2011

最近チェックした商品履歴

Loading...